Novel therapeutic approach: ligands for PPARgamma and retinoid receptors induce apoptosis in bcl-2-positive human breast cancer cells.
about
Chemotherapy and chemoprevention by thiazolidinedionesOmega-3 Fatty Acids and PPARgamma in CancerComputational identification and experimental validation of PPRE motifs in NHE1 and MnSOD genes of human.Damaged DNA binding protein 2 plays a role in breast cancer cell growthDeciphering downstream gene targets of PI3K/mTOR/p70S6K pathway in breast cancerVitamin D receptor, Retinoid X receptor and peroxisome proliferator-activated receptor γ are overexpressed in BRCA1 mutated breast cancer and predict prognosis.Troglitazone suppresses telomerase activity independently of PPARgamma in estrogen-receptor negative breast cancer cellsThe Key to Unlocking the Chemotherapeutic Potential of PPARγ Ligands: Having the Right Combination.Enhanced radiosensitivity and chemosensitivity of breast cancer cells by 2-deoxy-d-glucose in combination therapy.Management Strategies for Aggressive Cushing's Syndrome: From Macroadenomas to EctopicsPeroxisome proliferator-activated receptor-gamma ligands for the treatment of breast cancer.The peroxisome proliferator activated receptor gamma agonist pioglitazone increases functional expression of the glutamate transporter excitatory amino acid transporter 2 (EAAT2) in human glioblastoma cells.Phase I trial of exemestane in combination with metformin and rosiglitazone in nondiabetic obese postmenopausal women with hormone receptor-positive metastatic breast cancerA Role for the PPARgamma in Cancer Therapy.Thiazolidinediones as anti-cancer agents.Clinical Use of PPARgamma Ligands in Cancer.Synergistic Effects of PPARgamma Ligands and Retinoids in Cancer Treatment.Combined low doses of PPARgamma and RXR ligands trigger an intrinsic apoptotic pathway in human breast cancer cells.PPARγ maintains ERBB2-positive breast cancer stem cells.Expression of NAG-1, a transforming growth factor-beta superfamily member, by troglitazone requires the early growth response gene EGR-1.Glycolytic enzymes PGK1 and PKM2 as novel transcriptional targets of PPARγ in breast cancer pathophysiology.Rosiglitazone and retinoic acid inhibit proliferation and induce apoptosis in the HCT-15 human colorectal cancer cell lineTannic acid cross-linked collagen scaffolds and their anti-cancer potential in a tissue engineered breast implant.Multiple myeloma cells undergo differentiation upon exposure to rosiglitazone and all-trans retinoic acid.Troglitazone inhibits cell growth and induces apoptosis of B-cell acute lymphoblastic leukemia cells with t(14;18).Expression of NPM-RARalpha fusion gene in hematopoietic cells confers sensitivity to troglitazone-induced apoptosis.Correlation of thyroid hormone, retinoid X, peroxisome proliferator-activated, vitamin D and oestrogen/progesterone receptors in breast carcinoma.Peroxisome proliferator-activated receptor-gamma protects ERBB2-positive breast cancer cells from palmitate toxicity.[Radiosensitizing effect of conjugated linoleic acid on tumor cells MCF-7 and MDA-MB-231].Prognostic and biological significance of peroxisome proliferator-activated receptor-gamma in luminal breast cancer.
P2860
Q27011352-CD79FD08-419E-4358-BD2B-07246E8D3CBBQ28292907-958EA6C5-4410-457A-8DE6-6AE3A13F64C4Q30951265-0D7E03BC-85D8-4D58-BE46-7071076AFA15Q33330292-B97EBE4C-EFB8-459B-973F-5EC150C11B20Q33354798-1398935D-71C3-4E73-B8C6-1835DFBC0357Q33587654-3D0676F5-A474-4F56-A5B6-6AE65F3223C9Q33637896-197A3EAD-D577-4233-9F29-A099EDE74BB6Q36090448-37A76C78-F6BA-40D4-855A-ECE7976C25D7Q36091997-E7FB3F9D-BB4E-4D91-9317-202937CE51E5Q36184067-298C699F-1070-492C-8D0B-C9902821F78EQ36187022-03BA9C52-BE9C-4216-B4A5-E749F1AF5773Q36356318-1442EE44-4D83-4B50-B544-87B24EB49CEFQ36508067-71A73394-B1A6-41F6-90AE-A3FE1572FA85Q36691611-CD914F02-FD67-4EC7-B5CE-9ED41EF4F682Q37010188-F4358859-81A6-4DDB-94F5-268380D420E1Q37021288-586817D8-FCC0-4286-8161-82A57692222BQ37182802-7682619E-2D42-4696-98F4-7757D865FA24Q37316564-A03C1F0D-6DDB-4521-ADAC-DEBB3B096458Q37501777-D182D8E0-A79B-466D-8BD9-CE394E280A5BQ38347071-510AD182-C6A4-4D80-9205-84A7B4798D42Q38494271-6F8FAA4E-8605-43A4-B7E4-13EBA4189985Q39551235-6708447D-166D-468E-B281-4C1267C5F4A8Q39606410-75829CDE-9F9D-4977-B623-007A0E03654DQ39859934-A4776E44-6F03-43CB-BDC8-E43DD488C3ECQ40261116-AED33CCF-DDD5-4D42-A552-2D56459B5B98Q40631535-29468876-F5BD-422F-8ADE-8BDB9F8778ADQ41863209-16CAC736-3440-43BE-89FF-001B8E1F032CQ43120090-88989B58-0948-4D44-B683-ABE8A9A67686Q44820598-51060FB2-C59F-45A1-A88F-24FEEF1F903EQ50437809-FF6CCD94-B2C6-448A-9D08-586DEB106604
P2860
Novel therapeutic approach: ligands for PPARgamma and retinoid receptors induce apoptosis in bcl-2-positive human breast cancer cells.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh-hant
name
Novel therapeutic approach: li ...... ive human breast cancer cells.
@en
Novel therapeutic approach: li ...... ive human breast cancer cells.
@nl
type
label
Novel therapeutic approach: li ...... ive human breast cancer cells.
@en
Novel therapeutic approach: li ...... ive human breast cancer cells.
@nl
prefLabel
Novel therapeutic approach: li ...... ive human breast cancer cells.
@en
Novel therapeutic approach: li ...... ive human breast cancer cells.
@nl
P2093
P2860
P356
P1476
Novel therapeutic approach: li ...... ive human breast cancer cells.
@en
P2093
Koeffler HP
Possinger K
Williamson EA
P2860
P2888
P304
P356
10.1023/A:1016114026769
P407
P577
2002-07-01T00:00:00Z
P6179
1037815335